SLC16A3 and endometrial cancer: The investigation revealed that mutations in SLC16A3 were most prevalent in hepatobiliary cancer (> 5%), followed by endometrial cancer, pleural mesothelioma, breast cancer, and ovarian Epithelial tumor (> 4%).